Medscape
5 months agoAntiamyloid Gantenerumab Disappoints in Phase 3 Trials
Final results of phase 3 studies confirm that gantenerumab lowers amyloid plaque burden but does not slow clinical decline in patients with early Alzheimer's disease.
The GRADUATE I and II trials evaluated the safety and efficacy of gantenerumab compared with placebo over 27 months.
Secondary clinical outcomes did not support a beneficial clinical effect of the drug. [ more ]